300630 Stock Overview
Engages in the research and development, production, and sale of pharmaceutical drugs in China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Hainan Poly Pharm. Co., Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥10.32 |
| 52 Week High | CN¥27.10 |
| 52 Week Low | CN¥7.33 |
| Beta | 0.16 |
| 11 Month Change | -10.96% |
| 3 Month Change | -4.18% |
| 1 Year Change | -59.16% |
| 33 Year Change | -80.25% |
| 5 Year Change | -74.29% |
| Change since IPO | -44.88% |
Recent News & Updates
Recent updates
Shareholder Returns
| 300630 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 0.7% | 0.3% | -0.6% |
| 1Y | -59.2% | -7.9% | 3.2% |
Return vs Industry: 300630 underperformed the CN Pharmaceuticals industry which returned -9.4% over the past year.
Return vs Market: 300630 underperformed the CN Market which returned 2.8% over the past year.
Price Volatility
| 300630 volatility | |
|---|---|
| 300630 Average Weekly Movement | 12.4% |
| Pharmaceuticals Industry Average Movement | 7.4% |
| Market Average Movement | 8.4% |
| 10% most volatile stocks in CN Market | 12.6% |
| 10% least volatile stocks in CN Market | 5.7% |
Stable Share Price: 300630's share price has been volatile over the past 3 months compared to the CN market.
Volatility Over Time: 300630's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 1,565 | Min Hua Fan | english.hnpoly.com |
Hainan Poly Pharm. Co., Ltd. engages in the research and development, production, and sale of pharmaceutical drugs in China and internationally. The company’s formulations dosage forms comprise injections, tablets, capsules, dry suspensions/granules, eye drops and ointments, etc. covering various therapeutic areas, including cardiovascular, anti-allergy, antibiotics, gastrointestinal, dermatology, and non-steroid anti-inflammatory (NSAIDs). It offers pharmaceutical preparations and active pharmaceutical ingredients (APIs), other raw materials, excipients, prescription and non-prescription drugs, and contract manufacturing and contract development and manufacturing services.
Hainan Poly Pharm. Co., Ltd Fundamentals Summary
| 300630 fundamental statistics | |
|---|---|
| Market cap | CN¥4.63b |
| Earnings (TTM) | -CN¥106.04m |
| Revenue (TTM) | CN¥1.31b |
3.5x
P/S Ratio-43.7x
P/E RatioIs 300630 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300630 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.31b |
| Cost of Revenue | CN¥365.19m |
| Gross Profit | CN¥941.39m |
| Other Expenses | CN¥1.05b |
| Earnings | -CN¥106.04m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.24 |
| Gross Margin | 72.05% |
| Net Profit Margin | -8.12% |
| Debt/Equity Ratio | 96.7% |
How did 300630 perform over the long term?
See historical performance and comparison